# Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

> **NCT06238388** · PHASE1 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Chronic Kidney Disease Patients

## Interventions

- **DRUG:** HSK21542 Injection

## Key facts

- **NCT ID:** NCT06238388
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-10
- **Primary completion:** 2023-11-21
- **Final completion:** 2024-02-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238388, "Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06238388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*